Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04390737 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
A Phase 1 study of Advanced Solid Tumor and Peripheral T-Cell Lymphoma, sponsored by Haihe Biopharma Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 254
- Enrollment target
- 20
- Study locations
NCT04390737: Recruiting Phase 1 study of Advanced Solid Tumor and Peripheral T-Cell Lymphoma, sponsored by Haihe Biopharma Co..
NCT04390737 is a Phase 1 study of Advanced Solid Tumor and Peripheral T-Cell Lymphoma that is actively recruiting participants, run by Haihe Biopharma Co.. The registered enrollment target is 254 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (32% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04390737, a Phase 1 study of Advanced Solid Tumor and Peripheral T-Cell Lymphoma, is actively recruiting participants, sponsored by Haihe Biopharma Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 254 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.
Primary Outcome
Determine MTD of HH2853
Conditions Studied
Interventions
- DRUG HH2853 Tablets
Study Locations (20)
Beijing Municipality
- Beijing Cancer Hospital - Beijing
- Beijing Cancer Hospital - Beijing
- Beijing Jishuitan Hospital - Beijing
Liaoning
- Liaoning Cancer Hospital&Institute - Shenyang
- Shengjing Hospital Of China Medical University - Shenyang
Shanghai Municipality
- Shanghai Sixth People's Hospital - Shanghai
- Zhongshan Hospital Fudan University - Shanghai
Arizona
- Mayo Clinic - Phoenix
Florida
- Mayo Clinic - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Texas
- NEXT Oncology - San Antonio
Anhui
- The First Affiliated Hospital of Anhui Medical University - Hefei
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2020-09-08 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What NCT04390737 shows while recruiting
NCT04390737 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (32% higher).
The record links to 4 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which HH2853 Tablets is the first listed.
NCT04390737 names 20 study sites across 16 states, led by Beijing Municipality, Liaoning, Shanghai Municipality.
Frequently Asked Questions
What is clinical trial NCT04390737 about?
NCT04390737 is a clinical study titled "Evaluate the Safety and Clinical Activity of HH2853". This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.
What is the current status of trial NCT04390737?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 254 participants. The study started on 2020-09-08. Estimated completion is 2028-12-31.
What conditions does trial NCT04390737 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Peripheral T-Cell Lymphoma, Epithelioid Sarcoma, FL Lymphoma.
What interventions are being tested in trial NCT04390737?
The interventions under investigation include: HH2853 Tablets (DRUG).
Who is sponsoring clinical trial NCT04390737?
This trial is sponsored by Haihe Biopharma Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04390737 being conducted?
This trial has 20 study locations across Arizona, Florida, Minnesota, Texas, Anhui. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04390737's enrollment target sits among peer trials
254 45th of 189 higher than 145 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
- NCT06488144 · 254 participants · Phase 3
Rehabilitation for Arthritis of The Knee: mainTaining Improvement for Veterans
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI